Krystal Biotech (KRYS) Cash & Equivalents (2016 - 2026)

Krystal Biotech has reported Cash & Equivalents for 11 years, with the latest figure at $427.7 million in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $427.7 million, up 20.89% year-over-year; the trailing twelve-month figure through Jun 2026 was $427.7 million (up 20.89% YoY), and the FY2025 annual result was $496.3 million, up 43.91% from the prior year.
• Cash & Equivalents slipped to $427.7 million in Q2 2026, from $501.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $501.3 million in Q1 2026 and troughed at $140.7 million in Q1 2023.
• A 5-year average of $327.2 million and a median of $349.8 million in 2024 frame the typical range for Cash & Equivalents.
• The widest annual swing landed in 2022, when Cash & Equivalents sank 52.56%; it then surged 155.08% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $161.9 million in 2022, then surged by 121.33% to $358.3 million in 2023, then retreated by 3.76% to $344.9 million in 2024, then soared by 43.91% to $496.3 million in 2025, then decreased by 13.81% to $427.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $427.7 million in Q2 2026, $501.3 million in Q1 2026, and $496.3 million in Q4 2025.